• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xencor, Inc. - Common Stock (NQ:XNCR)

    11.74 -0.29 (-2.41%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 800,978
    Open 12.05
    Bid (Size) 10.01 (200)
    Ask (Size) 15.50 (100)
    Prev. Close 12.03
    Today's Range 11.68 - 12.25
    52wk Range 6.920 - 18.69
    Shares Outstanding 59,924,016
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
    From Xencor, Inc.
    Via Business Wire

    Performance

    YTD
    -21.3%
    -21.3%
    1 Month
    +1.7%
    +1.7%
    3 Month
    -30.1%
    -30.1%
    6 Month
    +38.3%
    +38.3%
    1 Year
    -9.6%
    -9.6%

    More News

    Read More
    News headline image
    Xencor to Participate at Upcoming Investor Conferences
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Beyond The Numbers: 4 Analysts Discuss Xencor Stock ↗
    Via Benzinga
    News headline image
    Critical Insights From Xencor Analyst Ratings: What You Need To Know ↗
    Via Benzinga
    News headline image
    Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor to Participate at Upcoming Investor Conferences
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Reports Third Quarter 2025 Financial Results
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
    From Xencor, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
    Via Benzinga
    News headline image
    Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor to Participate at Upcoming Investor Conferences
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor (XNCR) Q2 Revenue Jumps 82% ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Xencor Reports Second Quarter 2025 Financial Results
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Appoints Raymond Deshaies, Ph.D., to Board of Directors
    From Xencor, Inc.
    Via Business Wire
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Xencor Reports First Quarter 2025 Financial Results
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Appoints Todd Simpson to Board of Directors
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
    From Xencor, Inc.
    Via Business Wire
    News headline image
    Eliminating Some Screened Stocks ↗
    Via Talk Markets
    Topics Stocks / Equities
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Xencor, Inc. - Common Stock publicly traded?
    Yes, Xencor, Inc. - Common Stock is publicly traded.
    What exchange does Xencor, Inc. - Common Stock trade on?
    Xencor, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Xencor, Inc. - Common Stock?
    The ticker symbol for Xencor, Inc. - Common Stock is XNCR on the Nasdaq Stock Market
    What is the current price of Xencor, Inc. - Common Stock?
    The current price of Xencor, Inc. - Common Stock is 11.74
    When was Xencor, Inc. - Common Stock last traded?
    The last trade of Xencor, Inc. - Common Stock was at 03/17/26 04:00 PM ET
    What is the market capitalization of Xencor, Inc. - Common Stock?
    The market capitalization of Xencor, Inc. - Common Stock is 703.51M
    How many shares of Xencor, Inc. - Common Stock are outstanding?
    Xencor, Inc. - Common Stock has 704M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.